study, the Salk Institute researchers report that a protein known as transforming growth factor beta (TGF-Î²), considered a tumor suppressor in early cancer development, can actually promote cancer once a cell drifts into a pre-cancerous state.
The discovery-a surprise to the investigators-raises the tantalizing possibility that, with novel treatment, some cancers might be prevented before they even develop.
"Our work suggests it might be possible to halt cancer development in premalignant cells-those that are just a few divisions away from being normal," says the study's lead author, Fernando Lopez-Diaz, a researcher in the Regulatory Biology Laboratory at Salk.
Agents designed to inhibit TGF-Î² are already being tested against cancers that have already spread, says Beverly M. Emerson, a Salk professor, head of the lab and the study's senior author. "This study offers both significant insights into early cancer development and a new direction to explore in cancer treatment," she says. "It would be fantastic if a single agent could shut down both advanced cancer and cancer that is primed to develop."
Oncologists might also be able to use their discovery to predict whether premalignant cells in a patient are destined to become full-fledged cancer, Emerson adds. "Not all premalignant cells morph into cancer," she says. "Many self-destruct due to cellular protective mechanisms. But some will become tumors and, at this point, there is no way to predict which of these cells are a risk."
The two faces of TGF-Î²
TGF-Î² molecules are secreted proteins found in most human tissues. They play a number of different biological roles, including controlling cell proliferation and inflammation and assisting in wound healing.
The prevailing dogma in cancer research is that TGF-Î² signaling keep cells from morphing into cancer, says Lopez-Diaz. Scientists also recognized that cancer cells that "want" to spread learn how to use TGF-Î² wound-healing function to break from a tumor, he says.
Another protein, P53 is a known tumor suppressor. During the stress response that occurs as a cell becomes cancerous, and in response to chemotherapy, p53 attempts to repair DNA damage that has occurred, and, if not successful, p53 orders the cell to die. "The p53 pathway must be sabotaged for cells to become cancerous," Lopez-Diaz says. "This happens when its gene becomes mutated, if the p53 protein is exaggeratedly degraded or, less appreciated, if p53 biosynthesis is impeded."
The researchers conducted this study to learn exactly how p53 and TGF-Î² interact in cancer development. "For the past decade, everyone has believed that these two pathways work together in normal and premalignant cells to stop cancer, even though there was not much data to support this assumption," he says.
The team examined premalignant as well as cancer cells from breast and lung tumors and matched normal and premalignant breast cells from healthy women provided by scientists at the University of California San Francisco.
But no matter how many different ways they did their experiments, the Salk researchers found that TGF-Î² can interfere with cells damage responses in premalignant or cancer cells.
In fact, they found that TGF-Î² halts both the transcription of the p53 gene-the process by which cellular machinery reads the DNA code for a gene-and the subsequent process by which the corresponding p53 protein is produced, known as translation.
This could explain why, in about half of the breast tumors, including premalignant lesions, that the team studied at both UC San Francisco and at Sanford Burnham Medical Research Institute, when TGF-Î²1 signaling was highly activated, the levels of p53 were reduced, and vice versa-if the TGF-Î²1 pathway was reduced, there were high levels of p53. "A similar trend was seen with PUMA, a protein which induces cell death," Fernando Lopez-Diaz adds. "There was rather abundant PUMA protein when little TGF-Î²1 activation existed and vice versa."
"The bad face of TGF-Î² emerged within just a few cell divisions away from normality, allowing cells to avoid death," he says.
Filling in the cancer puzzle
This newfound immortality explains many oncologic mysteries, Lopez-Diaz says. "One is that it sheds light on how premalignant and early cancer cells are able to withstand the assault of chemotherapy and other treatments," he says.
It may explain why 77 percent of breast cancers have a normal p53 gene, and it further suggests a way that cancer cells can use both to metastasize and survive the journey to organs where they set up a new home.
"Because it helps cells avoid death, TGF-Î² can reduce the negative impact that the metastatic process has in the cancer cells," Lopez-Diaz says.
He adds that there is much work yet to do. "We want to understand the signals that turn TGF-Î² into a bad guy," he says. "If we know that, we might be able to inhibit those signals, and force damaged cells to die, as they should. That may offer us another treatment possibility, along with TGF-Î² inhibitors now being tested."
Other authors of the study are Sri Kripa Balakrishnan, from Salk; Philippe Gascard, Jianxin Zhao, and Thea D. Tlsty, from the University of California San Francisco; and Sonia V. del Rincon and Charles Spruck, from Sanford Burnham Medical Research Institute.
The study was funded by grants from the National Cancer Institute (U54CA143803), the Chambers Medical Foundation and a Cancer Center Grant (P30 CA014195). About the Salk Institute for Biological Studies:
The Salk Institute for Biological Studies is one of the world's preeminent basic research institutions, where internationally renowned faculty probe fundamental life science questions in a unique, collaborative, and creative environment. Focused both on discovery and on mentoring future generations of researchers, Salk scientists make groundbreaking contributions to our understanding of cancer, aging, Alzheimer's, diabetes and infectious diseases by studying neuroscience, genetics, cell and plant biology, and related disciplines.
Faculty achievements have been recognized with numerous honors, including Nobel Prizes and memberships in the National Academy of Sciences. Founded in 1960 by polio vaccine pioneer Jonas Salk, M.D., the Institute is an independent nonprofit organization and architectural landmark.